One hour-post administration, olomoucine suppressed microlgial proliferation, as well as reduced the tissue edema normally present during the early stages of glial scar formation.
Symptoms include desquamation or peeling, weak peripheral pulses, loss of peripheral sensation, edema and ultimately the death and loss of affected tissues.